Published in JAMA Neurology · View the paper (DOI)
Research reveals that GLP-1RAs and SGLT2i medications significantly reduce the risk of Alzheimer's disease and related dementias in people with type 2 diabetes. No significant difference was found between these two treatments.
Coverage from 2 institutions